# Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

> **NCT07266805** · PHASE3 · RECRUITING · sponsor: **Pharvaris Netherlands B.V.** · enrollment: 32 (estimated)

## Conditions studied

- Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)

## Interventions

- **DRUG:** Deucrictibant
- **DRUG:** Placebo
- **DRUG:** Deucrictibant
- **DRUG:** Placebo
- **DRUG:** Deucrictibant

## Key facts

- **NCT ID:** NCT07266805
- **Lead sponsor:** Pharvaris Netherlands B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-16
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07266805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07266805, "Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT07266805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*